Drug Profile
Cemdisiran - Alnylam Pharmaceuticals
Alternative Names: AD-62643; ALN 62643; ALN-CC5Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Regeneron Pharmaceuticals
- Class Drug conjugates; Oligonucleotides; Small interfering RNA
- Mechanism of Action Complement C5 inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
- Phase II Haemolytic uraemic syndrome; IgA nephropathy
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria(Combination therapy, In volunteers) in Belgium (SC, Injection)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Paroxysmal-nocturnal-haemoglobinuria(In volunteers) in Belgium (SC, Injection)
- 09 Dec 2023 Updated efficacy and adverse event data from a phase II trial in Paroxysmal nocturnal hemoglobinuria presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)